Open Access

Yi‑qi‑yang‑yin‑tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR

  • Authors:
    • Zhe‑Xin Shi
    • Hong‑Yu Li
    • Xiang‑Dong Yang
    • Hong Gao
    • De‑Guan Li
    • Wen‑Hua Yang
    • Fang Yao
    • Li‑Xiang Yan
  • View Affiliations

  • Published online on: September 26, 2017     https://doi.org/10.3892/ol.2017.7067
  • Pages: 6441-6448
  • Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the effects of serum containing a combination of yi‑qi‑yang‑yin‑tang (YQYYT) and daunorubicin (DNR) on multidrug resistance in KG1a leukemia stem cells (LSCs). The effects of YQYYT and DNR on proliferation, cell cycle progression and the expression of phosphatase and tensin homolog (PTEN), topoisomerase II (Topo II) and mechanistic target of rapamycin (mTOR) in KG1a cells were investigated in vitro using cell counting kit‑8 assay, flow cytometry, reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. It was revealed that YQYYT‑containing serum did not affect proliferation of KG1a cells compared with the blank group. Furthermore, there were no significant differences on the inhibition of proliferation among different groups at various concentrations of YQYYT. Treatment with YQYYT‑containing serum (volume, 20 and 40 µl) and DNR was able to significantly inhibit the proliferation of KG1a cells compared with the blank group. The inhibition rate in the treatment group with YQYYT‑containing serum (40 µl) and DNR for 48 h (72.5%) was higher compared with treatment for 24 h (60.4%, P<0.01). Treatment with YQYYT‑containing serum was able to promote G0 phase of KG1a cells into cell cycle in a dose‑ and time‑dependent manner, and significantly upregulated the mRNA expression of PTEN and Topo II, but did not affect mTOR expression compared with the blank group. Treatment with serum containing YQYYT alone did not directly affect the proliferation of KG1a cells, but when the cells were treated with a combination of YQYYT‑containing serum and DNR, the proliferation of KG1a cells was significantly inhibited in a dose‑ and time‑dependent manner. Furthermore, treatment with YQYYT‑containing serum was able to promote cell cycle progression of KG1a cells in the G0 phase and upregulate the expression of the negative regulatory genes PTEN and Topo II. These results indicated the potential of YQYYT to reverse multidrug resistance in LSCs.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shi ZX, Li HY, Yang XD, Gao H, Li DG, Yang WH, Yao F and Yan LX: Yi‑qi‑yang‑yin‑tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR. Oncol Lett 14: 6441-6448, 2017
APA
Shi, Z., Li, H., Yang, X., Gao, H., Li, D., Yang, W. ... Yan, L. (2017). Yi‑qi‑yang‑yin‑tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR. Oncology Letters, 14, 6441-6448. https://doi.org/10.3892/ol.2017.7067
MLA
Shi, Z., Li, H., Yang, X., Gao, H., Li, D., Yang, W., Yao, F., Yan, L."Yi‑qi‑yang‑yin‑tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR". Oncology Letters 14.6 (2017): 6441-6448.
Chicago
Shi, Z., Li, H., Yang, X., Gao, H., Li, D., Yang, W., Yao, F., Yan, L."Yi‑qi‑yang‑yin‑tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR". Oncology Letters 14, no. 6 (2017): 6441-6448. https://doi.org/10.3892/ol.2017.7067